Cassava Sciences in the NEWS Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent (US 12,186,3071) for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex (TSC). Simufilam is Cassava . . . This content is …
– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – …
Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care Conference Date: Monday, March 3, 2025: Time: 11:10 a.m. ET / 4:10 p.m. GMT Location: Boston, MA Leerink Partners 2025 Global Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …
Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted conditional marketing authorization to seladelpar in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults who have inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Now approved, Seladelpar (an orphan-designated . . . This content is for …
Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do not forget that Alnylam Pharmaceuticals (ALNY) is the leading RNAi Therapeutics. Keeping this in mind is important as RNAi therapeutic enables Alnylam to develop treatments together with future novel products created through gene editing, gene therapies, AI and other future technologies. In . . . This content is for …
What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect cancers early so they can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, state-of-the-art machine learning, software, and automation to detect and identify multiple deadly . . . This content is for paid subscribers. Please …
Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (
Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52 versus placebo. FVC is a measure of lung function. Initial data readouts of the FIBRONEER™-trials support a generally consistent safety and tolerability profile when compared to the Phase II IPF study, with overall adverse events comparable to …
Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, and was recently released from the hospital. Today, February 07, 2025, Eledon Pharmaceuticals (ELDN) announced that tegoprubart, its investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received . . . This content is …
Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults . . . This content is for …
Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorization for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for . . . This content is for paid subscribers. Please click here …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
